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Parkinson’s disease (PD)
• PD is the second most common neurodegenerative disorder.
• PD affects around 1% of the world-wide population over 60 years of age
and 4% in those above 80 years.
• Symptoms:
• Pathology: selective and progressive loss of dopaminergic neurons in
the substantia nigra pars compacta and the presence of Lewy bodies
(mainly α-synuclein).
• Only symptomatic treatment: dopamine substituents (L-dopa).
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• Saccharomyces cerevisiae: yeast most commonly used.
WHAT HAS BEEN ACHIEVED?
Genetics of Parkinson’s disease
At present 18 genetic loci (designated PARK1-18) have been
associated with the development of PD (Table 1).
Table 1. Description of PARK loci, corresponding gene, map positions, main function
and inheritance pattern.
PARK 
loci
Gene Map Position Function Inheritance
PARK1/4
α-synuclein
(SNCA)
4q21
Synaptic vesicle formation / 
membrane fusion
AD
PARK2 Parkin 6q25.2-q27 E3 ubiquitin ligase AR
PARK3 SPR? 2p13 Unknown
AD with reduced 
penetrance
PARK5 UCHL-1 4p14
Hydrolyze small C-terminal 
adducts of ubiquitin
AD
PARK6 PINK1 1p35-p36 Mitochondrial Kinase AR
PARK7 DJ-1 1p36
Cystein protease/redox-regulated 
chaperone
AR
PARK8 LRRK2 12q12 Kinase/GTPase activity AD
PARK9 ATP13A2 1p36 Lysosomal ATPase AR
PARK10 Unknown 1p32 Unknown Unclear
PARK11 GIGYF2 2q36-q37 Unknown AD
PARK12 Unknown Xq21-q25 Unknown Unclear
PARK13 Omi/HTRA2 2p13 Serine protease+ AD?
PARK14 PLA2G6 22q13.1 Phospolipid remodelling AR
PARK15 FBX07 22q12-q13 E3 ubiquitin protein ligase subunit AR
PARK16 Unknown 1q32 Unknown Unclear
PARK17 VPS35 16q11.2 Subunit of the retromer complex AD
PARK18 EIF4G1 3q27.1 Unknown AD
Mechanisms of neurodegeneration
There are different mechanisms involved in neurodegeneration of
Parkinson’s disease, such as mitochondrial dysfunction, oxidative stress,
altered proteolysis (proteasomal and lysosomal), inflammatory change and
excitotoxic mechanisms (Figure 2).
Figure 2. Key molecular mechanisms that are widely accepted to contribute to the
neurodegenerative process in PD. Double helix structures identify some of the common
gene mutations found in familial PD and brown arrows indicate where the altered protein
may interfere with cell function and overlap with known mechanisms of cell death in PD.
Blue double-headed arrows indicate molecular mechanisms that may not only be toxic in
their own right but importantly may also influence other molecular mechanisms known to be
features in PD. ROS, reactive oxygen species [1].
INTRODUCTION
Its cause remains unclear:
• Sporadic
· 90% of PD cases
• Genetic
· 10% of PD cases
Figure 1. The yeast 
characteristics make that the 
good model organism for PD.
.
* AD: autosomal dominant; AR: autosomal recessive.
CONCLUSIONS
[5] Klein, C., & Westenberger, A. (2012). Genetics of Parkinson’s disease. Cold Spring Harbor Perspectives in Medicine, 2(1), a008888. 
[6] Scarffe, L. a, Stevens, D. a, Dawson, V. L., & Dawson, T. M. (2014). Parkin and PINK1: much more than mitophagy. Trends in Neurosciences, 1–10. 
[7] Tenreiro, S., Munder, M. C., Alberti, S., & Outeiro, T. F. (2011). Harnessing the power of yeast to unravel the molecular basis of neurodegeneration. 
Journal of Neurochemistry, 127(4), 438–52. 
[8] Martin, I., Dawson, V. L., & Dawson, T. M. (2011). Recent advances in the genetics of Parkinson’s disease. Annual Review of Genomics Human 
Genetics, 12, 301–25.
[1] Dexter, D. T., & Jenner, P. (2013). Parkinson disease: from pathology to molecular disease mechanisms. Free Radical Biology & Medicine, 62, 132–44.
[2] Franssens, V., Bynens, T., Van den Brande, J., Vandermeeren, K., et al. (2013). The benefits of humanized yeast models to study Parkinson’s disease. 
Oxidative Medicine and Cellular Longevity, 2013, 760629.
[3] Miller-Fleming, L., Giorgini, F., & Outeiro, T. F. (2008). Yeast as a model for studying human neurodegenerative disorders. Biotechnology Journal, 
3(3), 325–38.
[4] Pereira, C., Bessa, C., Soares, J., Leão, M., et al. (2012). Contribution of yeast models to neurodegeneration research. Journal of Biomedicine & 
Biotechnology, 2012, 941232.
• Several research groups have developed great expertise in uncovering the cellular
aspects of α-synuclein toxicity using humanized yeast models.
• Yeast is a simple unicellular organism that has preserved many of the complex
processes that occur in neuronal cells. Thus, yeast constitutes a powerful system to
investigate the molecular basis underlying neurodegenerative disorders, such as PD.
• Yeast models strongly contributed to our current knowledge of the genes and
pathways involved in the most prominent human neurodegenerative diseases, as
demonstrated by their subsequent validation in higher eukaryotic models.
• Yeast models may facilitate strategies aimed to identify therapeutics for treating PD.
